International Flavors & Fragrances

IFF · NYSE

$91.21+$0.25 (+0.27%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $90.96

IFF analyst rating

BuyConsensus of 12 analysts over the last 12 months. 83% rate it a buy.

Strong buy0
Buy10
Hold2
Underperform0
Sell0

12-month price target · 19 analysts

Average $97.99 (+7.4% upside)

Low: $76.76
Now: $91.21
High: $110.25

Upgrades and downgrades

The latest rating actions, newest first

IFF analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Oct 16, 2026	Maintains	Overweight	$96.00 → $105.00	62%
Citigroup	Oct 7, 2026	Maintains	Buy	$101.00 → $100.00	53%
Argus Research	Oct 7, 2026	Maintains	Buy	$85.00 → $95.00	67%
Keybanc	Sep 11, 2026	Initiates	Sector Weight	—	30%
Barclays	Aug 7, 2026	Maintains	Overweight	$90.00 → $96.00	62%
UBS	Aug 6, 2026	Maintains	Neutral	$84.00 → $91.00	49%
Benchmark	Aug 6, 2026	Maintains	Buy	$100.00 → $105.00	34%
Morgan Stanley	Jul 1, 2026	Maintains	Overweight	$93.00 → $95.00	56%
Argus Research	Jun 30, 2026	Maintains	Buy	$80.00 → $85.00	67%
Citigroup	Jun 24, 2026	Maintains	Buy	$96.00 → $88.00	53%

The case for and against

Updated Feb 9, 2026

Bull case

International Flavors & Fragrances (IFF) has demonstrated a significant improvement in its financial performance, with the Return on Capital (ROC) rising from 2.77% to 5.32% over the last twelve months, signaling enhanced operational efficiency and profitability. The company also reported a year-over-year sales increase in its taste segment of 3%, with a more robust 6% growth on a currency-neutral basis, totaling $631 million, driven by strong demand across all regions. Furthermore, forecasts project an additional increase in ROC to 6.37% over the next twelve months, indicating a positive trajectory for the company's financial health.

Bear case

International Flavors & Fragrances is projected to experience a 5.56% decline in revenue over the next twelve months, with anticipated sales decreasing to approximately $10.68 billion following the divestiture of several key businesses, including Pharma Solutions and specific soy product lines. Despite the company maintaining a net sales revenue of $11.30 billion for the 12 months ending June 2025, this figure represents minimal year-over-year growth, indicating stability rather than growth potential. The ongoing divestiture activities and stagnant revenue raises concerns about the firm’s ability to meet long-term financial objectives and market expectations.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.